The Native Antigen Company Appoints Biozol and Shanghai Bioleaf as Distributors
The Native Antigen Company has revealed its appointment of Biozol and Shanghai Bioleaf as its distributors in Germany, Switzerland, Austria, and China
Supplier of reagents for vaccine research, The Native Antigen Company, has revealed its appointment of Biozol and Shanghai Bioleaf as its distributors in Germany, Switzerland, Austria, and China, in a July 11, 2019 press release.
Through the appointment of these two distributors, The Native Antigen Company will gain improved access into the aforementioned territories. Additionally, the distribution agreement will afford researchers in the covered regions to have access to the company’s native and recombinant viral and bacterial antigens, antibodies, and immunoassays.
Andy Lane, commercial director, The Native Antigen Company, said in the press release, “The Native Antigen Company partners with a number of specialist life-sciences distributors around the world, and we are pleased to be expanding this network across Europe and Asia. BIOZOL and Bioleaf are both well-established distributors who have extensive local knowledge and sales infrastructure in these overseas markets which will allow us to deliver our growing range of reagents to researchers working in academia and industry.”
Source: The Native Antigen Company
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
